<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802893</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00014296</org_study_id>
    <nct_id>NCT00802893</nct_id>
  </id_info>
  <brief_title>Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction</brief_title>
  <official_title>Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel Study of Oral 6R-BH4 in Subjects With Isolated Systolic Hypertension and Endothelial Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4
      to improve endothelial function, reduce systolic blood pressure and reduce arterial
      stiffness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By comparing values measured at different timepoints, the study is expected to provide
      insight regarding the ability of 6R-BH4, administered along with their currently prescribed
      antihypertension medications, to improve endothelial function, reduce SBP, and reduce
      arterial stiffness in patients with ISH and endothelial dysfunction
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We were unable to recruit any subjects into this study so no subjects completed the protocol.
    Therefore, we are unable to provide any conclusions.
  </why_stopped>
  <start_date type="Actual">December 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Efficacy of 6R-BH4 Versus Placebo to Improve Endothelia Function</measure>
    <time_frame>4-6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Efficacy of Oral 6R-BH4 Versus Dosage-equivalent Placebo to Improve Endothelia Function, to Reduce SBP, to Reduce Arterial Stiffness</measure>
    <time_frame>4-8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Isolated Systolic Hypertension</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Experimental Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6R-BH4</intervention_name>
    <description>6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period</description>
    <arm_group_label>Experimental Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo given BID for entire length of study</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No change in prescribed antihypertension medications within the previous 30 days

          -  Study staff able to visualize and measure the brachial artery diameter by high
             resolution vascular ultrasound required for FMD measurements

          -  ISH with the following mean seated BP: SBP &gt; 145 and &lt; 180 mmHg. Diastolic blood
             pressure &lt; 90mmHg

        Exclusion Criteria:

          -  Has known hypersensitivity to 6RBH4 or its excipients

          -  Pregnant or breastfeeding at screening

          -  Use of any investigational product or investigational medical device within 30 days
             prior to screening

          -  Current disease or condition that would interfere with study participation or safety
             such as the following: heart failure, atrial fibrillation, aortic valve disease,
             bleeding disorders, history of repeated syncope or vertigo, severe GERD, GI ulcer,
             symptomatic coronary or peripheral vascular disease, arrhythmia, serious neurologic
             disorders including seizures, organ transplant or organ failure

          -  Hypertension secondary to other medical conditions

          -  Any severe comorbid condition that would limit life expectancy to &lt;6 months

          -  Current use of any nicotine containing substances

          -  History of drug or alcohol abuse

          -  MI, stroke or surgery within 90 days before Screening Visit

          -  CABG within 6 months before the Screening Visit

          -  Serum creatinine &gt;2.0mg/dl or AST, ALT, GGT levels &gt;2times upper limit of normal

          -  Concomitant treatment with: any drug known to inhibit folate metabolism, any
             phosphodiesterase-5 or -3 inhibitor

          -  Previous treatment with any formulation of BH4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>July 20, 2017</results_first_submitted>
  <results_first_submitted_qc>August 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2017</results_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Isolated Systolic Hypertension with Endothelial Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>6R-BH4: 6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
OR
Placebo: placebo given BID for entire length of study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study terminated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>6R-BH4: 6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
OR
Placebo: placebo given BID for entire length of study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt;=40, years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Efficacy of 6R-BH4 Versus Placebo to Improve Endothelia Function</title>
        <time_frame>4-6 weeks</time_frame>
        <population>Due to difficulties recruiting, this study was terminated and no data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>6R-BH4: 6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
OR
Placebo: placebo given BID for entire length of study</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Efficacy of 6R-BH4 Versus Placebo to Improve Endothelia Function</title>
          <population>Due to difficulties recruiting, this study was terminated and no data was collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Efficacy of Oral 6R-BH4 Versus Dosage-equivalent Placebo to Improve Endothelia Function, to Reduce SBP, to Reduce Arterial Stiffness</title>
        <time_frame>4-8 weeks</time_frame>
        <population>Due to difficulties recruiting, this study was terminated and no data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>6R-BH4: 6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
OR
Placebo: placebo given BID for entire length of study</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Efficacy of Oral 6R-BH4 Versus Dosage-equivalent Placebo to Improve Endothelia Function, to Reduce SBP, to Reduce Arterial Stiffness</title>
          <population>Due to difficulties recruiting, this study was terminated and no data was collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Unknown. Due to difficulties recruiting, this study was terminated and no data was collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>6R-BH4: 6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
OR
Placebo: placebo given BID for entire length of study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johns Hopkins University Clinical Trials Program</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-6484</phone>
      <email>registerclinicaltrials@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

